Linked Life Data

17990102

Source:http://linkedlifedata.com/resource/pubmed/id/17990102

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2008-7-28
pubmed:abstractText
Taxanes (paclitaxel and docetaxel) comprise a class of mitotic inhibitors which considered highly active chemotherapeutic agents against cancer cells, and have become a cornerstone in the treatment of patients with early and advanced breast cancer. Following the initial generation of trials conducted to prove their efficacy, investigators turned to explore which taxane is superior in terms of efficacy, side effects, and quality of life based on head-to-head comparisons of paclitaxel versus docetaxel containing regimens. Moreover, many trials conducted to evaluate the optimal taxane dosing and schedule. This commentary discusses the ERASME 3 trial which compared the quality of life after four courses of doxorubicin combination with either paclitaxel or docetaxel, and also, it reviews all trials compared paclitaxel to docetaxel in both early and metastatic disease settings, in terms of efficacy, dosing, schedule, and toxicity profile.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0167-6806
pubmed:author
pubmed:issnType
Print
pubmed:volume
111
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
203-8
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.
pubmed:affiliation
Department of Internal Medicine, Indiana University School of Medicine, Indianapolis, IN 46202-5289, USA.
pubmed:publicationType
Journal Article, Review